Perseus Proteomics, Inc. (JP:4882) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Perseus Proteomics, Inc. recently showcased promising results for their radioisotope labeled antibody, PPMX-T002, at the EANM ’24 Congress in Germany. The antibody, designed to target cadherin 3 expressed in various solid tumors, demonstrated enhanced efficacy in preclinical trials when utilizing Actinium 225 over Yttrium 90. This development signals a potential breakthrough in cancer treatment strategies.
For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.